A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Conditions: Systemic Sclerosis Associated Interstitial Lung Disease; Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD); Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) Interventions: Drug: GenSci048; Drug: GenSci048 placebo Sponsors: Changchun GeneScience Pharmaceutical Co., Ltd.; West China Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials